Bio-Techne Singapore Pte. Ltd. operates the COMET™ platform, a fully automated spatial biology system designed to extract proteomic and transcriptomic data from tissue samples - tumors, organs, and other specimens - without the time overhead that has historically locked spatial analysis behind long development cycles. The company is part of Bio-Techne's Spatial Biology Division, which bundles microfluidic chip technology with compatible workflows to move research from assay development to cohort analysis in weeks rather than months.
The technical surface is clean: proprietary microfluidic chips handle sample preparation and multiplexing, but the platform accepts off-the-shelf, label-free primary antibodies rather than locking users into proprietary reagent stacks. This design choice matters operationally - it reduces researcher friction and keeps lab economics straightforward. The system integrates with ACD's RNAscope™ technology for multiomics data (protein plus RNA from the same sample), addressing the actual workflow need in immuno-oncology, neuroscience, and immunology labs where single-modality analysis leaves too much on the table.
Founded in 2014 and headquartered in Switzerland, the company draws team depth from research backgrounds, which shapes how the platform addresses genuine pain points: traditional tissue analysis is slow, labor-intensive, and expensive at scale. The stated mission centers on accessibility - making spatial biology a standard capability rather than a specialized procedure. Operationally, that means automating the assay development loop and standardizing the handoff to data analysis, reducing the manual work that compounds timelines in published workflows.
